Regeneron Pharmaceuticals (REGN) EV/EBITDA history

Above its usual rangeAs of

REGN's EV/EBITDA of 18.2x is higher than 71% of its available weekly readings from the last five years.

5.7x19.0x32.4x Median 18.2x 2021202320252026
5.7x19.0x32.4x Median 18.2x 2021202320252026
5.7x19.0x32.4x Median 18.2x 2021202320252026
5.7x19.0x32.4x Median 18.2x 2021202320252026

Oct 25, 2021 to Oct 19, 2026. Shading: middle half of five-year readings.

Explore REGN on stockresearch.app